Isocitrate dehydrogenase mutations: A challenge to traditional views on the genesis and malignant progression of gliomas

GLIA

Volumn 59, Issue 8, 2011, Pages 1200-1204

  Weller, Michael ^a   Wick, Wolfgang ^b   von Deimling, Andreas ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Brain; Glioblastoma; Glioma; Isocitrate dehydrogenase; Mutation

Indexed keywords

2 HYDROXYGLUTARIC ACID; HYPOXIA INDUCIBLE FACTOR; ISOCITRATE DEHYDROGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER GRADING; CANCER GROWTH; CARCINOGENESIS; ENZYME ACTIVITY; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROGNOSIS;

BRAIN NEOPLASMS; DISEASE PROGRESSION; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MUTATION;

EID: 79957921481     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.21130     Document Type: Article

References (40)

1. Aghili M, Zahedi F, Rafiee E. 2009. Hydroxyglutaric aciduria and malignant brain tumor: A case report and literature review. J Neurooncol 91: 233-236.
2. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. 2008. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116: 597-602.
3. Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, Frattini M, Molinari F, Knowles M, Cerrato A, Rodolfo M, Scarpa A, Felicioni L, Buttitta F, Malatesta S, Marchetti A, Bardelli A. 2009. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 30: 7-11.
4. Bleeker FE, Atai NA, Lamba S, Jonker A, Rijkeboer D, Bosch KS, Tigchelaar W, Troost D, Vandertop WP, Bardelli A, Van Noorden CJ. 2010. The prognostic IDH1(R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol 119: 487-494.
5. Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A. 2009. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118: 599-601.
6. Capper D, Sahm F, Hartmann C, Meyermann R, von Deimling A, Schittenhelm J. 2010a. Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes. Am J Surg Pathol 34: 1199-204.
7. Capper D, Weissert S, Balss J, Habel A, Meyer J, Jäger D, Ackermann U, Tessmer C, Korshunov A, Zentgraf H, Hartmann C, von Deimling A. 2010b. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20: 245-254.
8. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM. 2009. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462: 739-744.
9. Dubbink HJ, Taal W, Van Marion R, Kros JM, Van Heuvel I, Bromberg JE, Zonnenberg BA, Zonnenberg CBL, Postma TJ, Gijtenbeek JMM, Boogerd W, Groenendijk FH, Smitt PAES, Dinjens WNM, Van den Bent MJ. 2009. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 73: 1792-1795.
10. Gravendeel LAM, Kloosterhof NK, Linda BC, Bralten LBC, Van Marion R, Dubbink HJ, Dinjens W, Bleeker FE, Hoogenraad CC, Michiels E, Kros JM, Van den Bent M, Sillevis Smitt PAE, French PJ. 2010. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. Human Mutat 31: E1186-E1199.
11. Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, Sasaki M, Jin S, Schenkein DP, Su SM, Dang L, Fantin VR, Mak TW. 2010. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 207: 339-344.
12. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken J, Wesseling P, Reifenberger G, von Deimling A. 2009. Type and frequency of IDH1 and IDH2 mutations in astrocytoma, oligodendroglioma and mixed oligoastrocytoma. Acta Neuropathol 118: 469-474.
13. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A. 2010. IDH1 mutation status defines distinct prognostic subgroups among anaplastic astrocytoma and glioblastoma patients and accounts for the unfavorable prognostic effect of higher age. Acta Neuropathol 120: 707-718.
14. Horbinski C, Kofler J, Kelly LM, Murdoch GH, Nikiforova MN. 2009. Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol 68: 1319-1325.
15. Ichimura K, Pearson DM, Kocialkowski S, Bäcklund LM, Chan R, Jones DTW, Collins VP. 2009. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro-Oncology 11: 341-347.
16. Kang MR, Kim MS, Oh JE, Kim YR, Song SY, Seo SI, Lee JY, Yoo NJ, Lee SH. 2009. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 125: 353-355.
17. Kloosterhof NK, Bralten LBC, Dubbink HJ, French PJ, Van den Bent MJ. 2010. Isocitrate dehydrogenase-1 mutations: A fundamentally new understanding of diffuse glioma? Lancet Oncol, in press.
18. Korshunov A, Meyer J, Capper D, Christians A, Remke M, Witt H, Pfister S, von Deimling A, Hartmann C. 2009. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 118: 401-405.
19. Kranendijk M, Struys EA, van Schaftingen E, Gibson KM, Kanhai WA, van der Knaap MS, Amiel J, Buist NR, Das AM, de Klerk JB, Feigenbaum AS, Grange DK, Hofstede FC, Holme E, Kirk EP, Korman SH, Morava E, Morris A, Smeitink J, Sukhai RN, Vallance H, Jakobs C, Salomons GS. 2010. IDH2 mutations in patients with D-2-hydroxyglutaric aciduria. Science 330: 336.
20. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD, Fulton LA, Locke DP, Magrini VJ, Abbott RM, Vickery TL, Reed JS, Robinson JS, Wylie T, Smith SM, Carmichael L, Eldred JM, Harris CC, Walker J, Peck JB, Du F, Dukes AF, Sanderson GE, Brummett AM, Clark E, McMichael JF, Meyer RJ, Schindler JK, Pohl CS, Wallis JW, Shi X, Lin L, Schmidt H, Tang Y, Haipek C, Wiechert ME, Ivy JV, Kalicki J, Elliott G, Ries RE, Payton JE, Westervelt P, Tomasson MH, Watson MA, Baty J, Heath S, Shannon WD, Nagarajan R, Link DC, Walter MJ, Graubert TA, DiPersio JF, Wilson RK, Ley TJ. 2009. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361: 1058-1066.
21. Murugan AK, Bojdani E, Xing M. 2010. Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem Biophys Res Commun 393: 555-559.
22. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. 2009. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15: 6002-6007.
23. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LAJr., Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. 2008. An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
24. Pollack IF, Hamilton RL, Sobol RW, Nikiforova MN, Lyons-Weiler MA, LaFramboise WA, Burger PC, Brat DJ, Rosenblum MK, Holmes EJ, Zhou T, Jakacki RI, for the Children's Oncology Group. 2010. IDH1 mutations are common in malignant gliomas arising in adolescents: A report from the Children's Oncology Group. Childs Nerv Syst, in press.
25. Sahm F, Capper D, Meyer J, Hartmann C, Herpel E, Andrulis M, Mechterheimer G, Petersen I, Paulus W, von Deimling A. 2010. Immunohistochemical analysis of 1844 human epithelial and hematopoietic tumors and sarcomas for IDH1R132H mutation. Histopathology, in press.
26. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K, Delattre JY. 2009. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27: 4150-4154.
27. Schlisio S. 2009. Neuronal apoptosis by prolyl hydroxylation: Implication in nervous system tumours and the Warburg conundrum. J Cell Mol Med 13: 4104-4112.
28. Seiz M, Tuettenberg J, Meyer J, Essig M, Schmieder K, Mawrin C, von Deimling A, Hartmann C. 2010. Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: Evidence for molecular subtypes. Acta Neuropathol 120: 261-267.
29. Smeitink J. 2010. Metabolism, gliomas, and IDH1. N Engl J Med 362: 1144-1145.
30. Sonoda Y, Kumabe T, Nakamura T, Saito R, Kanamori M, Yamashita Y, Suzuki H, Tominaga T. 2009. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci 100: 1996-1998.
31. Van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJB, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, Van Marion R, Kros JM, Dinjens WNM, Gorlia T, Sanson M. 2010. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: A report of the European Organization for research and treatment of Cancer Brain Tumor Group. Clin Cancer Res 16: 1597-1604.
32. Van Schaftingen E, Rzem R, Veiga-da-Cunha M. 2009. L-2-Hydroxyglutaric aciduria, a disorder of metabolite repair. J Inherit Metab Dis 32: 135-142.
33. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, Rabinowitz JD, Carroll M, Su SM, Sharp KA, Levine RL, Thompson CB. 2010. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17: 225-234.
34. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. 2009a. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174: 1149-1153.
35. Watanabe T, Vital A, Nobusawa S, Kleihues P, Ohgaki H. 2009b. Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome. Acta Neuropathol 117: 653-656.
36. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann R, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M, for the Neurooncology Working Group (NOA) of the German Cancer Society. 2009. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. J Clin Oncol 27: 5874-5880.
37. Yan H, Bigner DD, Velculescu V, Parsons DW. 2009a. Mutant metabolic enzymes are at the origin of gliomas. Cancer Res 69: 9157-9159.
38. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. 2009b. IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773.
39. Yazici N, Sarialioglu F, Alkan O, Kayaselcuk F, Erol I. 2009. L-2-hydroxyglutaric aciduria and brain tumors: A case report and review of the literature. J Pediatr Hematol Oncol 31: 865-869.
40. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z, Gong L, Peng Y, Ding J, Lei Q, Guan KL, Xiong Y. 2009. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1a. Science 324: 261-265.